Galectin Therapeutics Presents 3 Abstracts At The American Association For The Study Of Liver Diseases 2024 Liver Meeting
Galectin Therapeutics Presents 3 Abstracts At The American Association For The Study Of Liver Diseases 2024 Liver Meeting
galectin therapeutics在2024年美国肝病研究协会大会上提交了3个摘要。
- Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal hypertension in MASH cirrhosis
- Blinded central review system can be effectively set-up for evaluation of esophagogastoduodenoscopy (EGD) in large multi-center trial of patients with MASH cirrhosis and portal hypertension, facilitating utilization of this outcome as a critical endpoint in portal hypertension trials
- Approximately a third of patients with MASH cirrhosis and portal hypertension (PH) screened for the NAVIGATE trial had the incidental finding of varices on EGD, highlighting the need for screening EGDs in these patients
- NAVIGATE trial readout on track for December 2024
- NAVIGATE试验的患者群体基于非侵入性测试和临床标准，使用最新的MASH肝硬化门静脉高压治疗指南
- 在针对MASH肝硬化和门静脉高压患者的大型多中心试验中，可以有效地设置盲目中央审查系统来评估食管胃十二指肠镜检查（EGD），从而促进将该结果用作门静脉高压试验的关键终点
- 在接受NAVIGE试验筛查的MASH肝硬化和门静脉高压（PH）患者中，约有三分之一偶然发现EGD上有静脉曲张，这凸显了对这些患者进行EGD筛查的必要性
- NAVIGATE 试用版有望在 2024 年 12 月发布
NORCROSS, Ga., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the presentation of three posters on the ongoing NAVIGATE trial in patients with MASH cirrhosis and portal hypertension at the American Association for the Study of Liver Diseases (AASLD)'s annual meeting 2024 Liver Meeting, being held November 15-19, 2024 in San Diego, California.
乔治亚州诺克罗斯，2024年11月18日（GLOBE NEWSWIRE）——靶向半乳糖凝集素蛋白疗法的领先开发商Galectin Therapeutics, Inc.（纳斯达克股票代码：GALT）今天在11月举行的美国肝病研究协会（AASLD）2024年肝脏会议上发布了三张海报，介绍正在进行的针对MASH肝硬化和门静脉高压患者的NAVIGE试验 2024 年 15 月 19 日在加利福尼亚州圣地亚哥举行。
资讯热榜
更新时间